Study or Subgroup	Placebo/MTX Events	Total	JAKI+MTX Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
8.4.1 Peficitinib 25mg + MTX						
Kivitz 2017	0	17	0	15		Not estimable
Subtotal (95% CI)		**17**		**15**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
8.4.2 Peficitinib 50mg + MTX						
Kivitz 2017	0	17	0	18		Not estimable
Subtotal (95% CI)		**17**		**18**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
8.4.3 Peficitinib 100mg + MTX						
Kivitz 2017	0	17	0	19		Not estimable
Takeuchi 2019	1	63	1	162	57.2%	2.57 [0.16, 40.49]
Subtotal (95% CI)		**80**		**181**	**57.2%**	**2.57 [0.16, 40.49]**
Total events	1		1			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.67 (P = 0.50)						
8.4.4 Peficitinib 150mg + MTX						
Kivitz 2017	0	17	0	18		Not estimable
Takeuchi 2019	1	63	0	163	42.8%	7.69 [0.32, 186.26]
Subtotal (95% CI)		**80**		**181**	**42.8%**	**7.69 [0.32, 186.26]**
Total events	1		0			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.25 (P = 0.21)						
Total (95% CI)		**194**		**395**	**100.0%**	**4.11 [0.51, 33.05]**
Total events	2		1			
Heterogeneity: $Tau^2 = 0.00$; $Chi^2 = 0.26$, df = 1 (P = 0.61); $I^2 = 0\%$						
Test for overall effect: Z = 1.33 (P = 0.18)						
Test for subgroup differences: $Chi^2 = 0.26$, df = 1 (P = 0.61), $I^2 = 0\%$